Semaglutide: A Comprehensive Overview of its Therapeutic Role

Semaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist, represents a significant advance in treating metabolic disorders. It functions by targeting GLP-1 receptors to improve physiological challenges associated with these conditions.

Clinical studies demonstrate Semaglutide's effectiveness in blood sugar control, substantial weight loss, and cardioprotective and renoprotective effects. It has also received FDA approval for metabolic dysfunction-associated steatohepatitis (MASH). While gastrointestinal side effects are the main concern, the overall risk-benefit analysis strongly supports its increasing importance in metabolic therapy.

Semaglutide is proposed for treating patients with complex needs, such as Ty, who presents with high A1C, advanced chronic kidney disease, and adherence issues. Its ability to lower A1C by 1-2%, its safety in patients with eGFR above 15 mL/min/1.73 m², and its cardiovascular and renal benefits make it a suitable choice. The once-weekly dosing also aids in improving medication adherence, which is crucial for patients with cognitive difficulties.

Semaglutide works by stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and increasing satiety, leading to enhanced blood sugar control with low hypoglycemia risk. For Ty, these attributes, along with its low risk of hypoglycemia compared to other agents and its once-weekly administration, make it an optimal treatment choice that accommodates her kidney function and adherence challenges. The treatment plan emphasizes personalized blood sugar targets, continued use of existing medications like losartan, and crucial patient education to ensure safety and optimal outcomes.